TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03316729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is matching saline solution for intravenous infusion
Study: NCT03695926
Drug: [18F]MNI-1054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
Study: NCT03629925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA, Q3W, day1, I.V.; consecutive cycles
Study: NCT03504163
Drug: Bacillus Calmette-Guérin (BCG)
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
Study: NCT04258033
Drug: PLB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Study: NCT02677532
Drug: Sufentanil epidural bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus of 0.15 mcg/kg sufentanil
Study: NCT02531204
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02080234
Drug: GELOX
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [GELOX 100]
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
Study: NCT00802100
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tablets of 20 to 40 mg
Study: NCT03614364
Drug: nanoxel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
Study: NCT04267822
Drug: RV521 oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Study: NCT04267822
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Study: NCT00460096
Drug: Kamada-API
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04167982
Drug: Oral conventional-dose isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose isotretinoin
Study: NCT04167982
Drug: Oral low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose isotretinoin
Study: NCT00092989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 1 dose
Study: NCT04377620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered BID approximately 12 hours apart
Study: NCT01427257
Drug: Single Dose PB1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose PB1023 Formulation A
Study: NCT01427257
Drug: Single Dose PB1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose PB1023 Formulation B
Study: NCT01189604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of placebo, same infusion rates as for arm 2
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
Study: NCT01189604
Drug: ICI35,868 (propofol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
Study: NCT03021941
Drug: Elelyso 60 units/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive Elelyso 60 units/kg.
Study: NCT02997800
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study: NCT01780077
Drug: RXI-109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of RXI-109 at incision sites
Study: NCT01780077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of placebo at incision sites
Study: NCT01051193
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03196947
Drug: APO010
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
Study: NCT04418388
Drug: PBK-1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02571777
Drug: QVM149 150/50/160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02571777
Drug: QVM149 150/50/80
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02571777
Drug: QMF149 150/320
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02951130
Drug: Placebo (5% Dextrose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention is an intravenous infusion of milrinone or placebo
Study: NCT02571777
Drug: QMF149 150/160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03287609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections with pre-filled auto-injector pen at day 1 and at week 4.
Study: NCT04603456
Drug: Lacteol fort and Standardized Timothy Grass Pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
Study: NCT03725852
Drug: GLPG1205
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 will be provided as an oral hard gelatin capsule.
Study: NCT03725852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
Study: NCT01273181
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
Study: NCT02129348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02327195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of placebo (PO) will be given 2 hours prior to surgery
Study: NCT03062007
Drug: BI-CON-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
Study: NCT03043924
Drug: Cyproterone Acetate + estradiol
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily
Study: NCT03043924
Drug: Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
Study: NCT03142178
Drug: Experimental: 3VM1001 active 2g Cream 3 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 2g Cream with active ingredient administered 3 times daily
Study: NCT03142178
Drug: Experimental: 3VM1001 active 3g Cream 3 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 3g Cream with active ingredient administered 3 times daily
Study: NCT03142178
Drug: Experimental: 3VM1001 active 3g Cream 4 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 3g Cream with active ingredient administered 4 times daily
Study: NCT03142178
Drug: Placebo: 3VM1001 vehicle 2g Cream 3 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 placebo 2g vehicle Cream administered 3 times daily
Study: NCT03142178
Drug: Placebo: 3VM1001 vehicle 3g Cream 3 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 placebo 3g vehicle Cream administered 3 times daily
Study: NCT03142178
Drug: Placebo: 3VM1001 vehicle 3g Cream 4 times daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3VM1001 placebo 3g vehicle Cream administered 4 times daily
Study: NCT00406965
Drug: HAE1 (PRO98498)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01816529
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Study: NCT03907475
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03907475
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01584921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Study: NCT01303978
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00003870
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003870
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01756937
Drug: Imotun
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300.03mg/cap,orally, 1 capsule once daily for 24 weeks
Study: NCT01756937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule once daily for 24 weeks
Study: NCT00004109
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
Study: NCT02525523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00047606
Drug: IOP Lowering Medications
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03953820
Drug: Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
Study: NCT04480736
Drug: JNJ-64281802 Dosing Regimen X
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64281802 dosing regimen X will be administered orally.
Study: NCT04480736
Drug: JNJ-64281802 Dosing Regimen Y
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64281802 dosing regimen Y will be administered orally.
Study: NCT04480736
Drug: JNJ-64281802 Dosing Regimen Z
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64281802 dosing regimen Z will be administered orally.
Study: NCT03167905
Drug: Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entonox will be given upon request in non-epidural group.
Study: NCT03660839
Drug: Ferroquine (SSR97193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT03167905
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT00661141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03329508
Drug: P2B001 0.6/0.75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose extended release combination capsule of pramipexole and rasagiline
Study: NCT02365207
Drug: BCG strain of Mycobacterium bovis
Normalized name: Mycobacterium bovis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Study: NCT03308578
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Study: NCT00401778
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
Study: NCT05504603
Drug: BEAM pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
Study: NCT00969696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8Mg a day of a sugar pill
Study: NCT00017446
Drug: CP4071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus injection
Study: NCT00003487
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00515411
Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
Study: NCT00515411
Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter.
Study: NCT01658228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
Study: NCT00006111
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03493607
Drug: AMO-01
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
Study: NCT00532558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT00843856
Drug: tacrolimus and mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
Study: NCT03338972
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03828942
Drug: drug inducing hematological toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce hematological toxicities
Study: NCT03849651
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9
Study: NCT04341077
Drug: SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of fluzoparib on Day 1
Study: NCT05801068
Drug: Factor Xa Inhibitor
Normalized name: Direct factor Xa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
Study: NCT00963131
Drug: antioxidants tablets
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
Study: NCT00122811
Drug: Indapamide SR 1.5mg; Perindopril 2-4mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00099541
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02230800
Drug: Matching placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06281041
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or clopidogrel
Study: NCT00002711
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03567707
Drug: C-section - Placebo Seeding
Normalized name: Northside Hospital C-Section Mothers KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
Study: NCT04205305
Drug: conventional blood pressure control (labetalol, nicardipine)
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
Study: NCT04205305
Drug: intensive blood pressure control (labetalol, nicardipine)
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
Study: NCT04231331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo qd for 12 months
Study: NCT02902081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651403
Drug: TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.
Study: NCT00567489
Drug: Physioneal
Normalized name: Physioneal 40 with 1.36% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physioneal 40 or Physioneal 35
Study: NCT01534962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, BID; for a maximum of 112 days.
Study: NCT04752748
Drug: Drug protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48.
Study: NCT01041833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
Study: NCT02255799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily for 70 days.
Study: NCT04025879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01740609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01577680
Drug: Inhaled GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
Study: NCT00255125
Drug: Soy Supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).